Reinventing HCV Treatment: Past and Future Perspectives (Q30241881)

12 June 2017

1 reference

title

Reinventing HCV Treatment: Past and Future Perspectives (English)

1 reference

12 June 2017

Wendy Carter

1

1 reference

12 June 2017

Sarah Connelly

series ordinal

2

1 reference

12 June 2017

Kimberly Struble

series ordinal

3

1 reference

12 June 2017

publication date

22 September 2016

1 reference

The Journal of Clinical Pharmacology

12 June 2017

published in

1 reference

12 June 2017

volume

57

1 reference

12 June 2017

issue

3

1 reference

12 June 2017

page(s)

287-296

1 reference

Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome

12 June 2017

cites work

1 reference

Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: updated criteria and genotype assignment web resource

21 January 2018

1 reference

Distribution of hepatitis C virus genotypes in a diverse US integrated health care population

21 January 2018

1 reference

Global epidemiology and genotype distribution of the hepatitis C virus infection

21 January 2018

1 reference

Global distribution and prevalence of hepatitis C virus genotypes

21 January 2018

1 reference

Hepatitis C virus genotype 7, a new genotype originating from central Africa

21 January 2018

1 reference

Genetic diversity and evolution of hepatitis C virus--15 years on

21 January 2018

1 reference

A prophylactic hepatitis C virus vaccine: a distant peak still worth climbing.

21 January 2018

1 reference

Natural history of hepatitis C: its impact on clinical management

21 January 2018

1 reference

Coinfection with HIV-1 and HCV--a one-two punch

21 January 2018

1 reference

Data supporting updating estimates of the prevalence of chronic hepatitis B and C in the United States.

21 January 2018

1 reference

Toward a more accurate estimate of the prevalence of hepatitis C in the United States

21 January 2018

1 reference

The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007.

21 January 2018

1 reference

Rising Mortality Associated With Hepatitis C Virus in the United States, 2003-2013.

21 January 2018

1 reference

Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression

21 January 2018

1 reference

Animal models for the study of hepatitis C virus infection and related liver disease

21 January 2018

1 reference

Virology and cell biology of the hepatitis C virus life cycle: an update

21 January 2018

1 reference

New advances in the molecular biology of hepatitis C virus infection: towards the identification of new treatment targets

21 January 2018

1 reference

A siege of hepatitis: fighting a defiant virus

21 January 2018

1 reference

Resistance of Hepatitis C Virus to Inhibitors: Complexity and Clinical Implications

21 January 2018

1 reference

Hepatitis C virus drug resistance-associated substitutions: State of the art summary

21 January 2018

1 reference

A sustained viral response is associated with reduced liver-related morbidity and mortality in patients with hepatitis C virus

21 January 2018

1 reference

A sustained virologic response reduces risk of all-cause mortality in patients with hepatitis C.

21 January 2018

1 reference

Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis.

21 January 2018

1 reference

Long-Term Treatment Outcomes of Patients Infected With Hepatitis C Virus: A Systematic Review and Meta-analysis of the Survival Benefit of Achieving a Sustained Virological Response

21 January 2018

1 reference

Diagnosis, management, and treatment of hepatitis C: an update

21 January 2018

1 reference

Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group

21 January 2018

1 reference

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

21 January 2018

1 reference

Randomised, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C. The Swedish Study Group

21 January 2018

1 reference

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I

21 January 2018

1 reference

Limited effectiveness of antiviral treatment for hepatitis C in an urban HIV clinic

21 January 2018

1 reference

Appendix: The National Institutes of Health Consensus Development Conference Management of Hepatitis C 2002.

21 January 2018

1 reference

Predictive factors associated with hepatitis C antiviral therapy response

21 January 2018

1 reference

Management of direct-acting antiviral agent failures

21 January 2018

1 reference

Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy

21 January 2018

1 reference

Antiviral therapy of hepatitis C in 2014: do we need resistance testing?

21 January 2018

1 reference

Successes and Challenges on the Road to Cure Hepatitis C

21 January 2018

1 reference

The importance of resistance to direct antiviral drugs in HCV infection in clinical practice

21 January 2018

1 reference

Resistance analysis of baseline and treatment-emergent variants in hepatitis C virus genotype 1 in the AVIATOR study with paritaprevir-ritonavir, ombitasvir, and dasabuvir

21 January 2018

1 reference

Prevalence of Resistance-Associated Substitutions in HCV NS5A, NS5B, or NS3 and Outcomes of Treatment With Ledipasvir and Sofosbuvir

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/JCPH.830

1 reference

12 June 2017

1 reference